image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 23.2
-1.61 %
$ 1.09 B
Market Cap
8.41
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AMPH stock under the worst case scenario is HIDDEN Compared to the current market price of 23.2 USD, Amphastar Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AMPH stock under the base case scenario is HIDDEN Compared to the current market price of 23.2 USD, Amphastar Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one AMPH stock under the best case scenario is HIDDEN Compared to the current market price of 23.2 USD, Amphastar Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AMPH

image
$40.0$40.0$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.020252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25Jul '25Jul '25
FINANCIALS
713 M REVENUE
10.62%
205 M OPERATING INCOME
4.28%
160 M NET INCOME
15.98%
213 M OPERATING CASH FLOW
16.28%
-125 M INVESTING CASH FLOW
80.75%
-81 M FINANCING CASH FLOW
-17.83%
171 M REVENUE
-8.58%
37.3 M OPERATING INCOME
-17.39%
25.3 M NET INCOME
-33.40%
35.1 M OPERATING CASH FLOW
20.86%
10.5 M INVESTING CASH FLOW
129.38%
-14.5 M FINANCING CASH FLOW
57.14%
Balance Sheet Amphastar Pharmaceuticals, Inc.
image
Current Assets 534 M
Cash & Short-Term Investments 222 M
Receivables 138 M
Other Current Assets 174 M
Non-Current Assets 1.04 B
Long-Term Investments 11 M
PP&E 345 M
Other Non-Current Assets 688 M
14.05 %8.75 %11.06 %21.85 %43.60 %Total Assets$1.6b
Current Liabilities 174 M
Accounts Payable 30.5 M
Short-Term Debt 7.04 M
Other Current Liabilities 136 M
Non-Current Liabilities 671 M
Long-Term Debt 644 M
Other Non-Current Liabilities 27.9 M
3.61 %16.12 %76.14 %3.30 %Total Liabilities$845.2m
EFFICIENCY
Earnings Waterfall Amphastar Pharmaceuticals, Inc.
image
Revenue 713 M
Cost Of Revenue 339 M
Gross Profit 374 M
Operating Expenses 168 M
Operating Income 205 M
Other Expenses 45.9 M
Net Income 160 M
800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00713m(339m)374m(168m)205m(46m)160mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
52.45% GROSS MARGIN
52.45%
28.82% OPERATING MARGIN
28.82%
22.38% NET MARGIN
22.38%
21.78% ROE
21.78%
10.11% ROA
10.11%
12.28% ROIC
12.28%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Amphastar Pharmaceuticals, Inc.
image
180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 160 M
Depreciation & Amortization 57.2 M
Capital Expenditures -41 M
Stock-Based Compensation 24.4 M
Change in Working Capital -14.5 M
Others 3.82 M
Free Cash Flow 172 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Amphastar Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for AMPH of $50.3 , with forecasts ranging from a low of $32 to a high of $71 .
AMPH Lowest Price Target Wall Street Target
32 USD 37.93%
AMPH Average Price Target Wall Street Target
50.3 USD 116.95%
AMPH Highest Price Target Wall Street Target
71 USD 206.03%
Price
Max Price Target
Min Price Target
Average Price Target
757570706565606055555050454540403535303025252020Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Amphastar Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
24.9 K USD 1
3-6 MONTHS
159 K USD 2
6-9 MONTHS
2.35 M USD 4
9-12 MONTHS
1.67 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5th, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. accessnewswire.com - 1 month ago
Amphastar Pharmaceuticals: Navigating Through An Inflection Year Amphastar Pharmaceuticals posted Q1 results last week that beat the bottom-line consensus. The stock appears cheap at under eight times forward earnings, but the company is going through an 'inflection year' with flat revenue growth and declining profits. Growth should return in 2026 thanks to upcoming product launches.  Is the stock cheap enough to buy the recent dip in the shares? seekingalpha.com - 1 month ago
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Bank of America Health Care Conference on Wednesday, May 14th, 2025, at 1:40 pm PT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. accessnewswire.com - 2 months ago
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants David Amsellem - Piper Sandler Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Ekaterina Knyazkova - JPMorgan Operator Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 2 months ago
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.04 per share a year ago. zacks.com - 2 months ago
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025 Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2025. First Quarter Highlights Net revenues of $170.5 million for the first quarter GAAP net income of $25.3 million, or $0.51 per share, for the first quarter Adjusted non-GAAP net income of $36.9 million, or $0.74 per share, for the first quarter Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "We are confident in the potential of our portfolio, particularly with the growth of BAQSIMI® and Primatene MIST®, and the promising pipeline of biosimilars and proprietary products. accessnewswire.com - 2 months ago
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock? Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately. zacks.com - 2 months ago
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. accessnewswire.com - 2 months ago
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. accessnewswire.com - 3 months ago
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that International Medication Systems, Ltd. ("IMS"), a subsidiary of Amphastar Pharmaceuticals, Inc. ("Amphastar") received a Drug Shortage Assistance Award from the U.S. Food and Drug Administration ("FDA"). accessnewswire.com - 3 months ago
New Strong Sell Stocks for March 24th AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025. zacks.com - 3 months ago
8. Profile Summary

Amphastar Pharmaceuticals, Inc. AMPH

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.09 B
Dividend Yield 0.00%
Description Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Contact 11570 6th Street, Rancho Cucamonga, CA, 91730 https://www.amphastar.com
IPO Date June 25, 2014
Employees 2028
Officers Dr. Ziping Luo Ph.D. Chairman of the Board, Chief Scientist & Chief Operating Officer Dr. Yongfeng Zhang Ph.D. Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director Mr. William J. Peters M.B.A. Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director Tony Marrs M.B.A., M.P.H., M.S. Executive Vice President of Regulatory Affairs & Clinical Operations Mr. Rong Zhou M.S. Senior EVice President of Production & EVP of Scientific Affairs Mr. Dan Dischner M.B.A. Senior Vice President of Human Resources & Corporate Communication Mr. Jacob Liawatidewi M.B.A. Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director